Radiotheranostics Market Size, Share and Trends Analysis 2026 to 2035
What is Radiotheranostics Market Size?
Global Radiotheranostics Market Size is valued at USD 2.61 Billion in 2025 and is predicted to reach USD 5.05 Billion by the year 2035 at an 7.2% CAGR during the forecast period for 2026 to 2035.
Radiotheranostics Market Size, Share & Trends Analysis Report By Radioisotope, By Source (Nuclear Reactors, Cyclotrons), By Approach, By Application(Oncology, Non-Oncology), By End-User, By Region, And Segment Forecasts, 2026 to 2035.
|
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Radiotheranostics Market Key Takeaways:
|
Key Industry Insights & Findings from the Report:
- The global radio theranostics market is expected to be driven by the expanding role of nuclear medicine in managing various chronic diseases and the rising demand for precision medicine.
- An increasing number of cancer cases are prompting healthcare providers to seek out radiotheranostics, which is leading to growth in the market.
- North America dominated the market and accounted for a revenue share of global revenue in 2025.
- The high cost of radiopharmaceuticals and radiotheranostics procedures can be a burden for both patients and healthcare providers.
Radiotheranostics is a division of radiology that combines molecular imaging (primarily PET and SPECT) with targeted radionuclide therapy, which involves the use of small molecules, peptides, and/or antibodies as carriers for therapeutic radionuclides, typically those emitting -, -, or auger-radiation. The approval of new radiotheranostic agents such as 177Lu-DOTATATE and 177Lu-PSMA-617, as well as the availability of companion diagnostic agents (such as 68Ga-DOTATATE and 68Ga-PSMA-11, respectively), has fueled a resurgence of interest in the field, fueling a slew of clinical trials testing novel radiotheranostics.
Increased public-private funding for target research initiatives, growing public awareness of the advantages of alpha radio immunotherapy-based targeted cancer treatment, and increased product innovations and development due to global technological advancements is expected to create lucrative opportunities for market participants during the forecast period. Hospital budget cuts, particularly during the pandemic, a lack of sufficient infrastructure in low- and middle-income nations, and an unfavorable reimbursement environment are all anticipated to pose challenges to the market throughout the projection period.
Increasing investment in R&D, particularly in developed and developing economies, for medical instruments and devices will further open up lucrative market expansion opportunities. The nuclear medical field's research and development capabilities also support the market growth rate. Growing numbers of strategic alliances and partnerships between public and private players are opening up lucrative new market opportunities for the funding and use of cutting-edge technology.
Competitive Landscape
Some major key players in the Radiotheranostics market
- Novartis AG
- Telix Pharmaceuticals
- Curium
- ITM Isotope Technologies
- Eli Lilly (via POINT Biopharma)
- AstraZeneca (via Fusion Pharmaceuticals)
- Radiopharm Theranostics
- Advanced Accelerator Applications (AAA)
- Ratio Therapeutics
- Radionetics Oncology
Market Segmentation:
The radiotheranostics market is segmented on the radioisotope, source, approach, applications and end users. Based on radioisotope, the market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, 18F, y-90, lutetium (lu) 177, copper (Cu) 67, copper (Cu) 64, others. Based on source, the market is segmented into Nuclear Reactors, Cyclotrons. Based on approach market is segmented into Targeted Therapeutic (Rx), Companion Diagnostic (DX). Based on application, the radiotheranostics market is segmented into oncology (thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma, lymphoma, others) and non-oncology (joint infections, arthritis, bone pain, others). Based on end-use, the radiotheranostics market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies and others.
The 177 Lu segment witnessed growth at a rapid rate
177 Lu segment grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. The majority of radioisotopes are employed in oncology for radiation therapy or diagnosis. Theranostics frequently utilized in diagnosing and treating neuroendocrine tumors include 68 Ga DONATE and 177 Lu DOTATOC. The main causes of the intense interest in the clinical application of this radionuclide are its good nuclear properties and the simplicity of obtaining high activity levels of 177Lu.
Cyclotrons are expected to expand at the fastest CAGR during forecast period.
Cyclotrons are fast evolving and will play an increasingly significant role in the pharmaceutical industry, particularly in advanced medical imaging techniques, since radiopharmaceuticals generated by cyclotrons are exceptionally effective at identifying various diseases.
The North American radiotheranostics market holds a significant revenue share in the region.
The North American radiotheranostics market is expected to register the highest market share in revenue soon because of the region's robust healthcare infrastructure, rising overweight population, large patient population suffering from chronic diseases like cancer, coronary artery disease, and strokes, and increased research activity. In addition, Asia Pacific is projected to grow rapidly in the global radiotheranostics market. However, this business is still expected to have substantial development potential due to the expanding number of clinical settings where flow cytometry is used.
Recent Developments:
- In January 2024, Lantheus broadened its portfolio of radiopharmaceuticals for the treatment of cancer by entering into strategic partnerships with Perspective Therapeutics. These strategic transactions increased the size of the pipeline and established a route for significant progress in the treatment of neuroendocrine tumors as well as prostate cancer.
Global Radiotheranostics Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 2.61 billion |
| Revenue Forecast In 2035 | USD 5.05 billion |
| Growth Rate CAGR | CAGR of 7.2% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2024 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Radioisotope, Source, Approach, Application, End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Novartis AG, Bayer AG, Telix Pharmaceuticals, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), AstraZeneca (via Fusion Pharmaceuticals), Radiopharm Theranostics, Nordic Nanovector, Y-mAbs Therapeutics, Ratio Therapeutics, Radionetics Oncology |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Radiotheranostics Market-
Radiotheranostics Market By Radioisotope:
- Technetium-99
- Gallium-68
- Iodine-131
- Iodine-123
- 18F
- Y-90
- Lutetium (Lu) 177
- Copper (Cu) 67
- Copper (Cu) 64
- Others (18F with Y-90)
Radiotheranostics Market By Source
- Nuclear Reactors
- Cyclotrons
Radiotheranostics Market By Approach
- Targeted Therapeutic (Rx)
- Companion Diagnostic (DX)
Radiotheranostics Market By Application:
- Oncology
- Thyroid Cancer
- Neuroendocrine Cancer
- Hepatocellular Carcinoma
- Multiple Myeloma
- Lymphoma
- Others
- Non-Oncology
- Joint Infections
- Arthritis
- Bone Pain
- Others
Radiotheranostics Market By End User:
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
North America Radiotheranostics Market By Country,
- U.S.
- Canada
Europe Radiotheranostics Market By Country,
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Radiotheranostics Market By Country,
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Radiotheranostics Market By Country,
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Radiotheranostics Market By Country,
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Radiotheranostics Market Size is valued at USD 2.61 billion in 2025 and is predicted to reach USD 5.05 billion by the year 2035.
Radiotheranostics Market expected to grow at a 7.2% CAGR during the forecast period for 2026-2035
Novartis AG, Bayer AG, Telix Pharmaceuticals, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), AstraZeneca (via Fusion Pharmaceuticals), Rad
Radiotheranostics market is segmented on the radioisotope, source, approach, applications and end users. Based on radioisotope, the market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, 18F, y-90, lutetium (lu) 177, copper (Cu) 67, copper (Cu) 64,.
North American region is leading the the Radiotheranostics Market.